Previous 10 | Next 10 |
naphtalina/iStock via Getty Images Arena Pharmaceuticals ([[ARNA]] +2.1%) has recovered after a loss of nearly 4% Tuesday that followed an announcement of a strategic collaboration agreement with Aristea Therapeutics. Per the terms, Arena will make a $60M upfront payment to Aristea in ad...
Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral ...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Douglas J. Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceut...
Cannabis REITs are riding a seemingly never-ending 'high' since bursting onto the scene in the late 2010s, thriving in the murky and often contradictory regulatory framework of legalized marijuana. The ongoing federal prohibition - and the resulting limit on access to traditional bank...
Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94. Viking Global added Bank of America while reducing JPMorgan Chase and dropping Walt Disney. The top three positions are Microsoft, BridgeBio Pharma, and Fidelity Nat...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steven Schoch to the Company's Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in ...
The FDA has granted Orphan Drug Designation status to Arena Pharmaceuticals' (ARNA) etrasimod, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE), a chronic, allergic inflammatory disease of the esophagus.Among the benef...
– EoE affects approximately 135,000 in the US and an estimated 132,000 patients in the EU4 and United Kingdom – Currently no FDA approved therapies in the US for the treatment of EoE Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that th...
Arena Pharmaceuticals (ARNA) announces that the first participant has been randomized in a mid-stage trial of IV temanogrel for the potential treatment of coronary microvascular obstruction ((cMVO)) in patients undergoing percutaneous coronary intervention ((PCI)).The trial, which is exp...
Palm Beach, FL – June 8, 2021 – The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe… and even the seemingly ever increasing Cannabidiol markets. The global COVID-19 pandemic outbreak has had an unprec...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...